Tocilizumab for the treatment of rheumatoid arthritis

No abstract is available for this paper.

• Publication year

  2010

• Venue

  Expert Review of Clinical Immunology

• Publication date

  2010-11-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1586/eci.10.70PMID 20979549
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Minimal influence of tocilizumab on IFN-γ synthesis by tuberculosis antigens

  2010cited by this paper
• Successful treatment with tocilizumab in a patient with refractory adult-onset Still's disease (AOSD).

  2010cited by this paper
• Tocilizumab Ameliorates Clinical Symptoms in Polymyalgia Rheumatica

  2010cited by this paper
• Rheumatology

  2010cited by this paper
• Rapid and sustained improvement in bone and cartilage turnover markers with the anti-interleukin-6 receptor inhibitor tocilizumab plus methotrexate in rheumatoid arthritis patients with an inadequate response to methotrexate: results from a substudy of the multicenter double-blind, placebo-controlle

  2010cited by this paper
• Excellent therapeutic effect of tocilizumab on intestinal amyloid a deposition secondary to active rheumatoid arthritis

  2010cited by this paper
• Portuguese guidelines for the use of biological agents in rheumatoid arthritis - March 2010 update.

  2010cited by this paper
• Mixed response to tocilizumab for ankylosing spondylitis

  2010cited by this paper
• Treatment of a patient with remitting seronegative, symmetrical synovitis with pitting oedema with a humanized anti-interleukin-6 receptor antibody, tocilizumab.

  2010cited by this paper
• Safety and efficacy profiles of tocilizumab monotherapy in Japanese patients with rheumatoid arthritis: meta-analysis of six initial trials and five long-term extensions

  2010cited by this paper
• Current evidence for the management of rheumatoid arthritis with biological disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of RA

  2010cited by this paper
• Tocilizumab in systemic lupus erythematosus: data on safety, preliminary efficacy, and impact on circulating plasma cells from an open-label phase I dosage-escalation study.

  2010cited by this paper
• Empfehlungen der Deutschen Gesellschaft für Rheumatologie zum Einsatz von Tocilizumab bei der rheumatoiden Arthritis (Februar 2010)

  2010cited by this paper
• Japan College of Rheumatology 2009 guidelines for the use of tocilizumab, a humanized anti-interleukin-6 receptor monoclonal antibody, in rheumatoid arthritis

  2009cited by this paper
• A case report of a patient with refractory adult-onset Still’s disease who was successfully treated with tocilizumab over 6 years

  2009cited by this paper
• Rapid improvement of AA amyloidosis with humanised anti-interleukin 6 receptor antibody treatment

  2009cited by this paper
• Glucocorticoid and cyclosporine refractory adult onset Still’s disease successfully treated with tocilizumab

  2009cited by this paper
• Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study

  2009cited by this paper
• Tocilizumab dramatically ameliorated life-threatening diarrhea due to secondary amyloidosis associated with rheumatoid arthritis

  2009cited by this paper
• Will treatment of rheumatoid arthritis with an IL-6R inhibitor help facilitate the ‘age of remission’?

  2009cited by this paper
• Anti-interleukin 6: first line in rheumatoid arthritis?

  2009cited by this paper
• Successful treatment of reactive arthritis with a humanized anti-interleukin-6 receptor antibody, tocilizumab.

  2009cited by this paper
• Sustained response to tocilizumab, anti-interleukin-6 receptor antibody, in two patients with refractory relapsing polychondritis.

  2008cited by this paper
• Long-term safety and efficacy of tocilizumab, an anti-IL-6 receptor monoclonal antibody, in monotherapy, in patients with rheumatoid arthritis (the STREAM study): evidence of safety and efficacy in a 5-year extension study

  2008cited by this paper
• Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial.

  2008cited by this paper
• IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial

  2008cited by this paper
• Study of active controlled tocilizumab monotherapy for rheumatoid arthritis patients with an inadequate response to methotrexate (SATORI): significant reduction in disease activity and serum vascular endothelial growth factor by IL-6 receptor inhibition therapy

  2008cited by this paper
• Successful treatment of a patient with Takayasu arteritis using a humanized anti-interleukin-6 receptor antibody.

  2008cited by this paper
• Mycobacterial disease in patients with rheumatic disease

  2008cited by this paper
• Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti-IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease.

  2008cited by this paper
• When patients with rheumatoid arthritis fail tumour necrosis factor inhibitors: what is the next step?

  2008cited by this paper
• Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study.

  2008cited by this paper
• The recombinant humanized anti-IL-6 receptor antibody tocilizumab, an innovative drug for the treatment of rheumatoid arthritis

  2008cited by this paper
• Tocilizumab for multirefractory adult-onset Still’s disease

  2008cited by this paper
• Portuguese guidelines for the use of biological agents in rheumatoid arthritis--December 2007 update.

  2007cited by this paper
• Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an x ray reader-blinded randomised controlled trial of tocilizumab

  2007cited by this paper
• New therapies for treatment of rheumatoid arthritis.

  2007cited by this paper
• Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate.

  2006cited by this paper
• Successful use of a humanized anti-interleukin-6 receptor antibody, tocilizumab, to treat amyloid A amyloidosis complicating juvenile idiopathic arthritis.

  2006cited by this paper
• Interleukin-6.

  2005cited by this paper
• Interleukin-6: from basic science to medicine--40 years in immunology.

  2005cited by this paper
• Humanized anti-interleukin-6 receptor antibody

  2005cited by this paper
• Essential role of STAT3 in cytokine‐driven NF‐κB‐mediated serum amyloid A gene expression

  2005cited by this paper
• Outcome of late-onset rheumatoid arthritis

  2005cited by this paper
• Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: a multicenter, double-blind, placebo-controlled trial.

  2004cited by this paper
• A pilot randomized trial of a human anti-interleukin-6 receptor monoclonal antibody in active Crohn's disease.

  2004cited by this paper
• IL-6 plays a critical role in the synergistic induction of human serum amyloid A (SAA) gene when stimulated with proinflammatory cytokines as analyzed with an SAA isoform real-time quantitative RT-PCR assay system.

  2004cited by this paper
• Toxicity, pharmacokinetics, and dose-finding study of repetitive treatment with the humanized anti-interleukin 6 receptor antibody MRA in rheumatoid arthritis. Phase I/II clinical study.

  2003cited by this paper
• Therapeutic benefit of blocking interleukin-6 activity with an anti-interleukin-6 receptor monoclonal antibody in rheumatoid arthritis: a randomized, double-blind, placebo-controlled, dose-escalation trial.

  2002cited by this paper
• Humanized monoclonal anti-interleukin-6 receptor antibody for treatment of intractable adult-onset Still's disease.

  2002cited by this paper
• Interleukin 6 plays a key role in the development of antigen-induced arthritis.

  1998cited by this paper
• Structure and function of a new STAT-induced STAT inhibitor

  1997cited by this paper
• Cytokine signal transduction.

  1995cited by this paper
• Interleukin-6 family of cytokines and gp130.

  1995cited by this paper
• Cytokine signal transduction.

  1994cited by this paper
• Activation of JAK2 kinase mediated by the interleukin 6 signal transducer gp130.

  1994cited by this paper
• Impaired immune and acute-phase responses in interleukin-6-deficient mice

  1994cited by this paper
• IL-6-induced homodimerization of gp130 and associated activation of a tyrosine kinase.

  1993cited by this paper
• Soluble forms of the interleukin-6 signal-transducing receptor component gp130 in human serum possessing a potential to inhibit signals through membrane-anchored gp130.

  1993cited by this paper
• Pathogenic significance of interleukin-6 (IL-6/BSF-2) in Castleman's disease.

  1989cited by this paper
• The biology of interleukin-6.

  1989cited by this paper
• Excessive production of interleukin 6/B cell stimulatory factor‐2 in rheumatoid arthritis

  1988cited by this paper
• Human B-cell differentiation factor defined by an anti-peptide antibody and its possible role in autoantibody production.

  1987cited by this paper

• IL-6 and Olfactory Dysfunction: Focus on Changes, Effects, and Mechanisms

  2025cites this paper
• Considerations for the use of biological therapies in elderly patients with rheumatoid arthritis

  2024cites this paper
• LZM008, a proposed tocilizumab biosimilar: Pharmacokinetics, safety, and immunogenicity profiles compared with ACTEMRA® in Chinese healthy male subjects

  2023cites this paper
• Real-world retention rates of biologics in patients with rheumatoid arthritis

  2023cites this paper
• Inflammation in COVID-19: A Risk for Superinfections

  2022cites this paper
• Utility of Myositis-Specific Autoantibodies for Treatment Selection in Myositis

  2022cites this paper
• Interleukin-6 cytokine: An overview of the immune regulation, immune dysregulation, and therapeutic approach.

  2022cites this paper
• Secondary Infections in Patients with COVID-19 Pneumonia Treated with Tocilizumab Compared to Those Not Treated with Tocilizumab: A Retrospective Study at a Tertiary Hospital in Kenya

  2022cites this paper
• The role of cytokines in migraine: A systematic review

  2022cites this paper
• Analysis of hematological parameters in rheumatoid arthritis patients receiving biological therapy: contribution to prevention of avoidable hematological complications

  2022cites this paper
• Immunomodulatory agents for COVID-19 treatment: possible mechanism of action and immunopathology features

  2022cites this paper
• Targeting IL‐6 to prevent cardiac allograft rejection

  2022cites this paper
• E3 ubiquitin ligase NEDD4L negatively regulates keratinocyte hyperplasia by promoting GP130 degradation

  2021cites this paper
• Cardiovascular Risk in Rheumatoid Arthritis

  2021cites this paper
• Pharmacotherapeutic agents for the management of COVID-19 patients with preexisting cardiovascular disease

  2021cites this paper
• Perioperative management with biologics on severe aortic valve regurgitation caused by Behçet syndrome: the experience from a single center

  2021cites this paper
• Neurological Consequences of SARS-CoV-2 Infection and Concurrence of Treatment-Induced Neuropsychiatric Adverse Events in COVID-19 Patients: Navigating the Uncharted

  2021cites this paper
• Novel coronavirus pathogen in humans and animals: an overview on its social impact, economic impact, and potential treatments

  2021cites this paper
• Rheumatic immune-related adverse events from checkpoint inhibitor therapy: a case series

  2021cites this paper
• Subcutaneous tocilizumab in adults with severe and critical COVID-19: A prospective open-label uncontrolled multicenter trial

  2020cites this paper
• Predicting treatment response to IL6R blockers in rheumatoid arthritis

  2020cites this paper
• Cardiovascular Impairment in COVID-19: Learning From Current Options for Cardiovascular Anti-Inflammatory Therapy

  2020cites this paper
• Assessing the Value of Sarilumab Monotherapy for Adults with Moderately to Severely Active Rheumatoid Arthritis: A Cost-Effectiveness Analysis.

  2019cites this paper
• Targeting STAT3 signaling in kidney disease.

  2019cites this paper
• Rheumatology practice in Japan: challenges and opportunities

  2019cites this paper
• Simple and rapid analysis of tocilizumab using HPLC-fluorescence detection method.

  2019cites this paper
• Clinicopathological features of TAFRO syndrome complicated by acquired hemophilia A and development of cardiopulmonary arrest that were successfully treated with VA-ECMO and tocilizumab

  2019cites this paper
• Immune mechanisms in chronic rheumatic muscle inflammation, myositis

  2018cites this paper
• The Two-Faced Cytokine IL-6 in Host Defense and Diseases

  2018cites this paper
• Retrospektive Analyse des Therapieverlaufs und kardiovaskulären Risikoprofils bei Patienten mit Rheumatoider Arthritis unter immunsuppressiver Therapie

  2018influential citation
• Central nervous system involvement in rheumatoid arthritis patients and the potential implications of using biological agents.

  2018cites this paper
• Efficacy of Anti-IL6-Receptor Tocilizumab in Refractory Cystoid Macular Edema of Birdshot Retinochoroidopathy Report of Two Cases and Literature Review

  2017cites this paper
• Chapter 6 – Rheumatoid Arthritis

  2017cites this paper
• Translating Autoimmune Pathogenesis into Targeted Therapies for Systemic Sclerosis

  2017cites this paper
• Inflammatory Arthritis: A Newly Recognized Adverse Event of Immune Checkpoint Blockade

  2017cites this paper
• [Macrophage activation syndrome secondary to tocilizumab: Myth or reality?].

  2016cites this paper
• Tocilizumab in severe and refractory Behcet's disease: Four cases and literature review.

  2016cites this paper
• Use and effectiveness of tocilizumab among patients with rheumatoid arthritis: an observational study from the British Society for Rheumatology Biologics Register for rheumatoid arthritis

  2016cites this paper
• The Clinical and Cost Effectiveness of Apremilast for Treating Active Psoriatic Arthritis: A Critique of the Evidence

  2016cites this paper
• Characterization of the anti-inflammation mechanism for the AO herbal extract.

  2016cites this paper
• From physiology to disease and targeted therapy: interleukin-6 in inflammation and inflammation-associated carcinogenesis

  2015cites this paper
• IL-6-driven STAT signalling in circulating CD4+ lymphocytes is a marker for early anticitrullinated peptide antibody-negative rheumatoid arthritis

  2015cites this paper
• Involvement of Mast Cells in α7 Nicotinic Receptor Agonist Exacerbation of Freund's Complete Adjuvant–Induced Monoarthritis in Mice

  2015cites this paper
• Pretreatment Prediction of Individual Rheumatoid Arthritis Patients’ Response to Anti-Cytokine Therapy Using Serum Cytokine/Chemokine/Soluble Receptor Biomarkers

  2015cites this paper
• Anakinra and Tocilizumab Enhance Survival and Function of Human Islets during Culture: Implications for Clinical Islet Transplantation

  2014cites this paper
• Immediate infusional reactions to intravenous immunobiological agents for the treatment of autoimmune diseases: experience of 2126 procedures in a non-oncologic infusion centre.

  2014cites this paper
• Severe Pulmonary Suppuration with Infection-Induced Systemic Inflammatory Response Syndrome following Tongue Cancer Surgery in a Patient Undergoing Tocilizumab Therapy for Rheumatoid Arthritis

  2014influential citation
• Interleukin 6 and Rheumatoid Arthritis

  2014cites this paper
• The 2013 BSR and BHPR guideline for the use of intravenous tocilizumab in the treatment of adult patients with rheumatoid arthritis.

  2014cites this paper
• Reações infusionais imediatas a agentes imunobiológicos endovenosos no tratamento de doenças autoimunes: experiência de 2.126 procedimentos em um centro de infusão não oncológico

  2014cites this paper
• Aberrant histone acetylation contributes to elevated interleukin-6 production in rheumatoid arthritis synovial fibroblasts.

  2014cites this paper
• Molecular biology of calcific aortic valve disease: towards new pharmacological therapies

  2014cites this paper
• REVISTA BRASILEIRA DE REUMATOLOGIA

  2014cites this paper
• Targeting of Interleukin-6 for the Treatment of Rheumatoid Arthritis: A Review and Update

  2014influential citation
• Methotrexate: an old new drug in autoimmune disease

  2014cites this paper
• The role of X-ray imaging and musculoskeletal ultrasound in the diagnosis and management of rheumatoid arthritis

  2014cites this paper
• P2Y2 receptor represses IL-6 expression by valve interstitial cells through Akt: implication for calcific aortic valve disease.

  2014cites this paper
• Tocilizumab in uveitis refractory to other biologic drugs: a study of 3 cases and a literature review.

  2014cites this paper
• Endothelial Interleukin‐6 Defines the Tumorigenic Potential of Primary Human Cancer Stem Cells

  2014cites this paper
• Effect of interleukin‐6 receptor blockade on feto‐maternal outcomes in a rat model of intrauterine inflammation

  2013cites this paper
• Weight change during pharmacological blockade of interleukin-6 or tumor necrosis factor-α in patients with inflammatory rheumatic disorders: a 16-week comparative study.

  2013cites this paper
• Interleukin 6 blockade-associated weight gain with abdominal enlargement in a patient with rheumatoid arthritis.

  2013cites this paper
• Immunotherapy of Tocilizumab for Rheumatoid Arthritis

  2013cites this paper
• A review of cost–effectiveness evaluations as part of national health technology assessments of biologic DMARDs in the treatment of rheumatoid arthritis

  2013influential citation
• Monoclonal antibodies in rheumatoid arthritis

  2013cites this paper
• Tocilizumab: An Updated Review of Its Use in the Treatment of Rheumatoid Arthritis and Its Application for Other Immune-Mediated Diseases

  2013cites this paper
• Current perspectives on tocilizumab for the treatment of rheumatoid arthritis: a review

  2013cites this paper
• Genetics of asthma susceptibility and severity.

  2012cites this paper
• A case of Behçet’s disease treated with a humanized anti-interleukin-6 receptor antibody, tocilizumab

  2012cites this paper
• Rhumatisme psoriasique chez deux patients en échec de traitement par le tocilizumab

  2012cites this paper
• A case of Behcet's disease treated with a humanized anti-interleukin-6 receptor antibody, tocilizumab

  2012cites this paper
• Therapeutic targeting of the interleukin-6 receptor.

  2012cites this paper
• Psoriatic arthritis in two patients with an inadequate response to treatment with tocilizumab.

  2012cites this paper
• Canadian Rheumatology Association Recommendations for Pharmacological Management of Rheumatoid Arthritis with Traditional and Biologic Disease-modifying Antirheumatic Drugs

  2012cites this paper
• Tocilizumab for the treatment of rheumatoid arthritis

  2012cites this paper
• Tocilizumab for the Treatment of Rheumatoid Arthritis and Other Systemic Autoimmune Diseases: Current Perspectives and Future Directions

  2012cites this paper
• Pathological Role of Interleukin-6 in Psoriatic Arthritis

  2012cites this paper
• The interleukin-6 receptor as a target for prevention of coronary heart disease: a mendelian randomisation analysis

  2012cites this paper
• The role of tocilizumab monotherapy in the management of rheumatoid arthritis: a review

  2012cites this paper
• Immunotherapeutic implication of IL-6 blockade.

  2012cites this paper
• Safety and Efficacy of Tocilizumab for the Treatment of Rheumatoid Arthritis

  2012cites this paper
• Interleukin 15 mediates joint destruction in Staphylococcus aureus arthritis.

  2012cites this paper
• Concordance of preclinical and clinical pharmacology and toxicology of therapeutic monoclonal antibodies and fusion proteins: cell surface targets

  2012cites this paper
• Successful aging as a continuum of functional independence: lessons from physical disability models of aging.

  2012cites this paper
• Access to the next wave of biologic therapies (Abatacept and Tocilizumab) for the treatment of rheumatoid arthritis in England and Wales

  2012cites this paper
• Tocilizumab for the Treatment of AA Amyloidosis

  2011cites this paper
• Successful treatment of acquired hemophilia A, complicated by chronic GVHD, with tocilizumab

  2011cites this paper
• Tocilizumab, a humanized anti‐interleukin‐6 receptor antibody, for the treatment of autoimmune disorders

  2011cites this paper
• Therapeutic effect of tocilizumab on two patients with polymyositis.

  2011cites this paper
• Interleukin 15 and 17 in Staphylococcus aureus arthritis

  2011cites this paper
• Anti‐interleukin‐6 receptor antibody, tocilizumab, for the treatment of autoimmune diseases

  2011influential citation
• TOCILIZUMAB FOR THE TREATMENT OF RHEUMATOID ARTHRITIS

  2011cites this paper
• Evidence Review Group approaches to the critical appraisal of manufacturer submissions for the NICE STA process: a mapping study and thematic analysis.

  2011cites this paper
• Tocilizumab, a humanized anti-interleukin-6 receptor antibody, ameliorated clinical symptoms and MRI findings of a patient with ankylosing spondylitis

  2011cites this paper
• Rôle de la phosphodiestérase spécifique de l'AMPc (PDE4) dans deux modèles d'inflammation chronique : le lupus érythémateux disséminé et l'asthme

  2010cites this paper
• Tocilizumab for rheumatoid arthritis.

  2010cites this paper
• Adalimumab for the treatment of rheumatoid arthritis

  2009cites this paper
• ▼Tocilizumab for rheumatoid arthritis

  2009cites this paper
• Biologics: Targets and Therapy Dovepress Monoclonal Antibodies in Rheumatoid Arthritis: Comparative Effectiveness of Tocilizumab with Tumor Necrosis Factor Inhibitors

  year unknowncites this paper